Literature DB >> 16596781

Retrograde signalling by endocannabinoids.

C W Vaughan1, M J Christie.   

Abstract

The cannabinoid neurotransmitter system comprises cannabinoid G protein-coupled membrane receptors (CB1 and CB2), endogenous cannabinoids (endocannabinoids), as well as mechanisms for their synthesis, membrane transport and metabolism. Within the brain the marijuana constituent delta9-tetrahydrocannabinol (THC) produces its pharmacological actions by acting on cannabinoid CB1 receptors. THC modulates neuronal excitability by inhibiting synaptic transmission via presynaptic CB1-mediated mechanisms. More recently, it has been established that physiological stimulation of neurons can induce the synthesis of endocannabinoids, which also modulate synaptic transmission via cannabinoid CB1 and other receptor systems. These endogenously synthesised endocannabinoids appear to act as retrograde signalling agents, reducing synaptic inputs onto the stimulated neuron in a highly selective and restricted manner. In this review we describe the cellular mechanisms underlying retrograde endocannabinoid signalling.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16596781     DOI: 10.1007/3-540-26573-2_12

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  28 in total

Review 1.  Potential Therapeutical Contributions of the Endocannabinoid System towards Aging and Alzheimer's Disease.

Authors:  Amandine E Bonnet; Yannick Marchalant
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

Review 2.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Authors:  Roger G Pertwee
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

Review 3.  Inflammation and aging: can endocannabinoids help?

Authors:  Yannick Marchalant; Holly M Brothers; Gary L Wenk
Journal:  Biomed Pharmacother       Date:  2008-03-14       Impact factor: 6.529

4.  Endocannabinoids block status epilepticus in cultured hippocampal neurons.

Authors:  Laxmikant S Deshpande; Robert E Blair; Julie M Ziobro; Sompong Sombati; Billy R Martin; Robert J DeLorenzo
Journal:  Eur J Pharmacol       Date:  2006-11-22       Impact factor: 4.432

5.  Photoperiodic changes in endocannabinoid levels and energetic responses to altered signalling at CB1 receptors in Siberian hamsters.

Authors:  J M Ho; N S Smith; S A Adams; H B Bradshaw; G E Demas
Journal:  J Neuroendocrinol       Date:  2012-07       Impact factor: 3.627

6.  Cross-sensitization and cross-tolerance between exogenous cannabinoid antinociception and endocannabinoid-mediated stress-induced analgesia.

Authors:  Richard L Suplita; Sarah A Eisenstein; Mark H Neely; Anna M Moise; Andrea G Hohmann
Journal:  Neuropharmacology       Date:  2007-07-19       Impact factor: 5.250

Review 7.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

Authors:  R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

Review 8.  Cannabinoids and multiple sclerosis.

Authors:  Roger G Pertwee
Journal:  Mol Neurobiol       Date:  2007-06-26       Impact factor: 5.590

9.  Development of pharmacoresistance to benzodiazepines but not cannabinoids in the hippocampal neuronal culture model of status epilepticus.

Authors:  Laxmikant S Deshpande; Robert E Blair; Nisha Nagarkatti; Sompong Sombati; Billy R Martin; Robert J DeLorenzo
Journal:  Exp Neurol       Date:  2007-01-09       Impact factor: 5.330

10.  Different forms of glycine- and GABA(A)-receptor mediated inhibitory synaptic transmission in mouse superficial and deep dorsal horn neurons.

Authors:  Wayne B Anderson; Brett A Graham; Natalie J Beveridge; Paul A Tooney; Alan M Brichta; Robert J Callister
Journal:  Mol Pain       Date:  2009-11-18       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.